Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology
This article was originally published in PharmAsia News
Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority
You may also be interested in...
Now studying stem-cell candidate MPC-150-IM in two 600-patient Phase III trials in advanced heart failure, the partners could complete the Phase III program more quickly and less expensively.
The Australian stem cell company said a Phase III trial being run by partner Teva and testing MPC-150-IM in chronic heart failure could finish earlier than expected because of an interim superiority analysis.
Australian Stem Cell Company Mesoblast To Get AU$170 Million Private Placement As Clinical Trials Ramp Up
Mesoblast Ltd., which Teva holds a 20% stake in, aims to raise AU$170 million by issuing new shares to a select group of existing and new global institutional investors.